Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Aytu Biopharma (AYTU) over the last 14 years, with Sep 2025 value amounting to $114,000.

  • Aytu Biopharma's Share-based Compensation fell 34.10% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $517,000, marking a year-over-year decrease of 76.02%. This contributed to the annual value of $576,000 for FY2025, which is 80.23% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Share-based Compensation is $114,000, which was up 0.88% from $113,000 recorded in Q2 2025.
  • Aytu Biopharma's 5-year Share-based Compensation high stood at $3.1 million for Q4 2022, and its period low was $113,000 during Q2 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $352,000 (2024), whereas its average is $491,364.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 476.52% in 2021, then crashed by 82.86% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Share-based Compensation stood at $1.2 million in 2021, then skyrocketed by 149.55% to $3.1 million in 2022, then crashed by 73.26% to $820,000 in 2023, then slumped by 81.59% to $151,000 in 2024, then slumped by 34.10% to $114,000 in 2025.
  • Its last three reported values are $114,000 in Q3 2025, $113,000 for Q2 2025, and $139,000 during Q1 2025.